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Despite its evidenced beneficial herbicidal, antibacterial, antiviral, antifungal, and antioxidant effects, the application of juglone 
(5-hydroxy-1,4,-naphthoquinone) is limited due to its low water solubility and allelopathic and toxic effects. In recent years, 
research has aimed to overcome these limitations by increasing its solubility and controlling its release through nanoparticular 
systems. This is the first study to have synthesised and characterised juglone-loaded polymeric nanoparticles and compared 
them with free juglone for cytotoxicity in mouse (L929 fibroblasts) and alfalfa cells and for mutagenic potential in 
Salmonella typhimurium TA98/100. Mouse and plant cells treated with free and nano-encapsulated juglone showed a 
decrease in cell viability in a dose and time-dependent manner, but this effect was significantly lower with the nano-
encapsulated form at lower doses. In the TA98 strain with S9, nano-encapsulated juglone did not exhibit mutagenic effects, 
unlike the free form. Since all results show that juglone encapsulation with polymeric nanoparticles reduced the toxic 
and mutagenic effects, it has a promising potential to be applied in medicine, food safety, and agriculture.
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Walnut preparations are used in traditional medicine for 
the treatment of many health problems such as fungal, 
bacterial, viral, and helminthic infections, hypotension, 
hypoglycaemia, and even cancer (1). Walnut has the highest 
concentrations of an allelochemical molecule which is an 
amber pigment largely responsible for its biological activity 
(Figure 1) (2). Juglone is found in the root, leaves, bark, 
and nuts of several walnut species of the Juglandaceae 
family, including Juglans nigra, Juglans regia, Juglans 
cinerea, and Carya illinoinensis (3). Even though it is poorly 
soluble in water, juglone will adversely affect plants 
growing around the tree (2, 4). In terms of its toxicity 
mechanisms, a number of studies have established that it 
causes cell death, disrupts the cell cycle, modifies DNA 
(especially in rapidly dividing cells), inhibits mRNA 
synthesis, alkylates basic protein thiol or amine groups, and 
reduces tumour suppressor levels (2, 5–7).
Nowadays, new antibiotics are needed to address 
increasing antimicrobial resistance, but their development 
and approval cannot keep up the pace with this issue (8). It 
is therefore essential to develop new antibacterials with 
different bacterial killing mechanisms than those of 
conventional antibiotics. Considering its high antimicrobial 
effect against infections, juglone bears a promise in this 
respect. It has already been evidenced for herbicidal (9), 
antibacterial (10–13), antiviral (14), antifungal (15, 16), 
antioxidant (13), antiparasitic (17), and anticancer (18–20) 
properties. However, its hydrophobic structure and high 
toxicity limit its application in biological systems (2, 4).
A promising strategy to overcome this limitation of 
juglone and many other materials comes with nanosized 
drug delivery systems, which have attracted considerable 
interest in recent years (21, 22). Nanoparticulate systems 
provide greater biocompatibility and bioavailability and 
lower the doses of active substances, still achieving the 
desired effect through controlled release (23, 24). This is 
particularly true for polymeric nanoparticles such as the 
poly (D,L-lactic-co-glycolic acid) (PLGA) polymer, as it 
increases biocompatibility and therapeutic index of active 
ingredients (Figure 1) (22). Biodegradation of PLGA does 
not lead to toxicity. Lactic acid from hydrolysis products 
enters the tricarboxylic acid cycle and is excreted as carbon 
dioxide and water. Glycolic acid is likewise metabolised to 
carbon dioxide and water or directly excreted from the 
kidneys (25).
The aim of this study was therefore to compare cytotoxic 
and mutagenic properties of juglone-loaded polymeric 
nanoparticles (JNPs) with those of free juglone. For this 
purpose, we encapsulated juglone in PLGA nanoparticles, 
and characterised their physicochemical and release profile. 
Then, for the first time in literature, we compared the 
cytotoxic activity of JNPs with juglone in plant cell (alfalfa) 
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and mouse cell culture (L929 fibroblast cells). Additionally, 
we investigated their mutagenic potential in Salmonella 
typhimurium strains TA98 and TA100 in culture media with 
or without the S9 metabolic activation system.
MATERIALS AND METHODS
Materials
Juglone (Mw: 174.15 g/mol, CAS Number: 481-39-0), 
polyvinyl alcohol (PVA, Mw 31–50 kDa, 87–89 % 
hydrolyzed, CAS Number: 9002-89-5), PLGA (50:50 
lactide:glicolide; inherent viscosity 0.45−0.60 dL/g, Mw 
~38−54 kDa,  CAS Number:  26780-50-7),  and 
dichloromethane (DCM, CAS Number: 75-09-2) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Plant suspension cultures were established from alfalfa 
(Medicago sativa cv Verco) seeds kindly provided by Dr 
Sa t ı  Uzun  (Un ive r s i ty  o f  E rc iyes ,  Turkey) . 
2,4-dichlorophenoxyacetic acid, kinetin, sucrose, and agar 
used for preparing the Murashige and Skoog (MS) medium 
were purchased from Sigma-Aldrich.
The mouse fibroblast cell line L929 was obtained from 
the American Type Culture Collection (ATCC, Manassas, 
VA, USA). Dulbecco’s modified Eagle’s medium (DMEM) 
/ Ham’s Nutrient Mixture F-12 medium, foetal bovine serum 
(FBS), penicillin, and L-glutamine used in the preparation 
of fibroblast cell cultures were purchased from Sigma-
Aldrich. The Ames Microplate Format Mutagenicity 
Assay™ 98/100 kit and strains were provided from Anaria-
Xenometrix (Mason, OH, USA). All the chemicals and 
solvents used for mutagenicity study were of analytical 
grade. Ultra-pure water was obtained from the Millipore 
MilliQ Gradient system (Merck Millipore, Burlington, MA, 
USA)
Nanoparticle synthesis and characterisation
Juglone-loaded nanoparticles (JNPs) were synthesised 
using the single-emulsion solvent evaporation method 
described in our previous study (16) with minor 
modifications. 20 mg of juglone and 100 mg of PLGA were 
first dissolved in 3.5 mL DCM and stirred to ensure that all 
materials were dissolved. The obtained organic phase was 
added dropwise to 8 mL of aqueous PVA solution (3 % w/v) 
over an ice bath, and the mixture was sonicated with a 
microtip probe sonicator (HD3100, Bandelin, Berlin, 
Germany, output power 100 W) at 80 % power for 2 min. 
The obtained oil-in-water (o/w) emulsion was then diluted 
in 35 mL of PVA solution (0.1 % w/v) and mixed on a 
magnetic stirrer at room temperature overnight for the 
organic solvent to evaporate. The obtained nanoparticles 
were centrifuged at 10,000xg for 40 min (Beckman Coulter, 
Allegra-X-30R) and washed three times with ultrapure 
water. After that, the suspensions were lyophilised and solid 
nanoparticles stored at -80 °C until use.
Encapsulation efficiency and drug loading were 
determined by indirect quantification using UV-vis 
spectroscopy (UV 1800, Shimadzu, Tokyo, Japan). UV 
absorbance of the supernatant was analysed at 424 nm in 
triplicate. Juglone concentration was calculated using a 
previously constructed standard calibration curve (26). 
Encapsulation efficiency (EE) and drug loading (DL) of 
juglone were calculated as follows:
EE% = Encapsulated juglone in NPs (mg)       [1]Encapsulated juglone amount (mg)
DL% = Encapsulated juglone in NPs (mg) x100  [2]Obtained nanoparticle amount (mg)
The mean diameter, particle size distribution, zeta 
potential (ζ), and polydispersity index (PDI) of the 
nanoparticles were investigated by photon correlation 
spectroscopy using a Zetasizer Nano ZS (Malvern, UK) 
instrument (27). Nanoparticles were also inspected for shape 
and surface morphology with scanning electron microscopy 
(SEM, A JSM-7001FA, Jeol, Japan) as previously described 
in our studies (10), with an acceleration voltage of 
10−30 kV. Successful encapsulation of juglone was 
evidenced with Fourier-transform infrared spectroscopy 
(FT-IR) using an IR-Prestige 21 FT-IR spectrophotometer 
(Shimadzu, Kyoto, Japan) in ATR mode. The FT-IR spectra 
ranging between 600 and 4000 cm-1 were obtained with 
resolution of 4 cm-1 (28).
Juglone release was established with a modified 
dissolution method in triplicate, in which 5 mg of 
nanoparticles were suspended in 2 mL of phosphate buffer 
saline (PBS) and incubated 37 °C in a shaking incubator 
(150 rpm) at pH of 7.2 (16). The suspensions were 
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Figure 1 Chemical structure of juglone (A) and poly (lactic-co-glycolic acid) (B)
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to 4 mL of 5–6 day old alfalfa suspension cultures under 
continuous agitation at 110 rpm in an orbital shaker. After 
24 and 48 h of incubation, cell suspensions (1 mL) were 
transferred to tubes and centrifuged at 445xg for 5 min to 
collect the cells. Cell viability was determined with the 
MTT assay with minor modifications (31). 100 µL of a 
5 mg/mL MTT solution was added to each tube and 
incubated in dark on a shaker at 24 °C for 2 h. The pellet 
was removed by centrifugation at 1000xg for 5 min and 
resuspended with 200 µL of DMSO for 10 min. The 
supernatant was placed on microplate and analysed at 
570 nm in a universal microplate reader. Cell viability (%) 
was calculated as follows:
Cell viability (%) =
OD value of treated cells
x100  [4]
OD value of untreated cells (control)
Bacterial cell mutagenicity and cytotoxicity evaluation
To determine juglone mutagenicity we chose the Ames 
MPF assay as a method that shows reverse mutagenicity in 
Salmonella typhimurium strains TA98 and TA100. These 
strains cannot grow in histidine-free media, since they have 
lost the ability to produce histidine due to point mutations 
(either frame-shift for TA98 or base-pair for TA100) in the 
histidine (His) operon. However, a new mutation in this 
operon (such as the one caused by juglone) reverts His 
auxotroph into a prototroph and reverts the initial mutation 
so that the strains can now grow in histidine-free media. 
Frozen stock cultures of S. typhimurium TA98 and TA100 
strains in histidine-free medium were thawed at room 
temperature and pipetted to be completely homogenised. 
They were prepared by incubating in tubes containing 
10 mL growth medium and 10 µL ampicillin (50 mg/mL) 
at 37 °C and shaking at 200 rpm for 16–18 h overnight. 
When the cultures reached spectrophotometric OD600 ≥2.0, 
they were ready for mutagenicity testing.
The mutagenic activity of free and nano-encapsulated 
juglone was determined with the Ames MPF™ 98/100 
bacterial reverse mutation assay (Anaria-Xenometrix, 
Mason, OH, USA) with or without the metabolic activation 
of the rat liver S9 microsomal fraction. The study was 
carried out in accordance with the kit protocol (32). 
2-nitrofluorene (2NF; 2 µg/mL), 4-nitroquinalone-N-oxide 
(4NQO; 0.1 µg/mL), and 2-aminoanthracene (2-AA; 2.5 µg/
mL for TA100, 1.0 µg/mL for TA98) were used as positive 
control (mutagens). Water (solvent) was used as negative 
control. The S9 metabolic activation system was prepared 
as a 30 % mix of S9 fraction and cofactors (32–34). Free 
and nano-encapsulated juglone stock concentrations were 
set to contain 5.7 mmol/L juglone. The final concentration 
of juglone applied to all wells ranged between 0.31 and 
10 µmol/L. Bacterial cultures in a 24-well plate were 
exposed to 10 µL of free or nano-encapsulated juglone stock 
solution for 90 min (37 °C, 250 rpm). The liquid exposure 
medium contained trace amounts of required histidine. In 
the presence of S9, the volume of the exposure medium 
was reduced as indicated in the kit to produce a 240 µL mix 
centrifuged and the obtained precipitates, resuspended with 
2 mL of fresh PBS, and supernatants analysed with UV-vis 
spectroscopy at 424 nm. The amount of released juglone 
was calculated using a previously constructed calibration 
curve (26).
Fibroblast cell cytotoxicity evaluation
L929 fibroblast cell lines were grown at 37 °C in 
DMEM/Ham’s Nutrient Mixture F-12 medium (1:1) 
supplemented with 10 % FBS, 100 µg/mL streptomycin, 
100 units/ mL penicillin, and 0.2 mmol/L L-glutamine in 
an atmosphere of 95 % air and 5 % CO2. The medium was 
changed every two days. The morphology of the cells was 
examined with an Olympus phase contrast microscope 
(Olympus CKX41, Tokyo, Japan) at 5x magnification.
The cytotoxic potential of juglone was quantified with 
the MTT assay (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (29) following the ISO 
10993-5 procedure (30). Briefly, 5×103 fibroblast cells per 
well were seeded in 96-well plates and incubated at 37 °C 
for 24 h and then exposed to free and nano-encapsulated 
juglone in concentrations of 5, 27, 83, 160, 250, 500, and 
1000 µmol/L suspended in DMEM/ Ham’s Nutrient Mixture 
F-12 medium (1:1). Following 24- and 48-hour incubation, 
the supernatant from each well was replaced with fresh 
MTT reagent in the final concentration of 50 µg/mL of 
medium. The cells were then incubated at 37 °C for 3 h, 
and their viability determined by measuring absorbance at 
570 nm in a universal microplate reader. Control growth 
was considered to be 100 % viable. Metabolic activity was 
expressed as mean±SD. Cell viability (%) was calculated 
as follows:
Cell viability (%) =
OD value of treated cells
x100  [3]
OD value of untreated cells (control)
Alfalfa cell cytotoxicity evaluation
Leaf explants (5–6 cm) removed from in vitro aseptic 
seedling of alfalfa were cultured on MS medium 
supplemented with 3 mg/L 2,4-dichlorophenoxyacetic acid, 
0.5 mg/L kinetin, 3 % (w/v) sucrose, and 0.8 % (w/v) agar 
for callusing. The pH of the medium was adjusted to 5.6 
before autoclaving at 121 °C for 20 min. After six weeks, 
cell suspension cultures were initiated in 150 mL 
Erlenmeyer flasks with 1 g of friable callus in 50 mL of MS 
liquid medium containing plant growth regulator used for 
the callus phase. The cultures were kept in a dark growth 
chamber at 24±2 °C under continuous agitation of 110 rpm 
in an orbital shaker. After 21 days, 30 mL of fresh medium 
was added to 10 mL of decanted suspension culture, and 
the suspensions were subcultured every 10 days by 
transferring 10–30 mL of fresh medium. Cell density was 
determined as ~1.5×105 cells /mL using the Thoma cell 
counting chamber. These cultures were used as stock.
Alfalfa cells were exposed to the same free and nano-
encapsulated juglone concentrations as the mouse cells. 100 
µL free or nano-encapsulated juglone solutions were added 
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of S9 and exposure medium containing bacterial culture. 
This mix was added to the wells containing juglone 
solutions, resulting in a total volume of 250 µL. At the end 
of exposure, each well of the 24-well plates received 2.6 mL 
of histidine-free indicator medium. 50 µL of the culture in 
each well was taken and distributed to a 384-well plate. 
After 48 h of incubation at 37 °C, the metabolism of 
prototroph cells that succeeded to reproduce in histidine-
free medium lowers the pH of the substrate, causing a 
change in colour from purple (bromosresol) to yellow as a 
result of the catabolic activity of the revertant bacteria. This 
colour is interpreted as a mutagenic effect, and each well 
is scored for either yellow (mutagenic effect or positive 
control) or purple (no-mutagenic effect or solvent control) 
(32, 34, 35).
Juglone cytotoxicity to the S. typhimurium TA98 and 
100 strains was investigated as described in the “pre-screen 
determination of dose range” section of the kit protocol 
(32). Only free juglone was evaluated, because we did not 
expect any problem with the solubility of the PLGA 
nanoparticle system, from which juglone is slowly released. 
The kit protocol recommends the use of 25 times higher 
stock sample concentrations than the highest concentration 
to be used in the mutagenicity study. However, as juglone 
water solubility is very low, we adjusted its concentration 
range from 2.5 to 80 µmol/L. Briefly, bacterial overnight 
cultures were incubated in exposure medium at 37 °C for 
90 min and measured spectrophotometrically at OD600. The 
results were evaluated according to turbidity and sediment. 
Being an indication of bacterial lysis, pure image is an 
indicator of a cytotoxic dose. The well containing a lower 
dose should be more blurred and have no sediment at the 
bottom. The highest concentration to be applied in the Ames 
assay was therefore the lowest sample concentration with 
the highest solubility and no cytotoxicity.
Statistical analysis
Cytotoxicity results [means of four (mammalian cells) 
and three (plant cells) independent treatments repeated for 
all groups, starting with the cell growth step] were analysed 
with a GraphPad Prism6 software (San Diego, CA, USA). 
The differences between JNPs and free juglone within each 
dose were determined using the t-test. P values <0.05 were 
considered significant. IC50 values were calculated using 
Prism6.
The criteria for the evaluation of mutagenicity results 
(means ± standard deviations of the number of revertant 
wells) were the number of positive wells and dose 
dependency (32, 34, 36). The data were evaluated with the 
cumulative binomial distribution test according to the 
manufacturer’s instructions. The increase of revertants 
relative to the solvent control was determined by dividing 
the mean number of positive wells (yellow well) at each 
dose with solvent control baseline, which is obtained by 
adding one standard deviation to the mean number of 
positive wells of the solvent control. A twofold or higher 
increase over baseline was considered a mutagenic effect. 
The dose-response relationship and the differences were 
considered significant when the binomial value was ≥99 % 
(21).
RESULTS AND DISCUSSION
Table 1 shows the physicochemical properties of JNPs. 
In terms of encapsulation efficiency and drug loading 
activities our results are compatible with similar reports in 
the literature (37–39).
JNPs had a narrow size distribution (Figure 2A), and 
were quite spherical, smooth, and homogeneous in size 
(Figure 2B SEM image).
Figure 2C compares the FT-IR absorbance spectra of 
free juglone, JNPs, and juglone-free PLGA nanoparticles. 
Juglone exhibited the main characteristic triple peaks at 
1593 cm-1 (C2=C3), 1635 cm
-1 (C4=O), and 1662 cm
-1 
(C1=O), while the peak at 1288 cm
-1 corresponds to the 
C5-O group. Unlike juglone, both PLGA and JNPs have a 
carbonyl group absorbance band at 1751 cm-1. A comparison 
of all three spectra clearly shows a similarity between JNPs 
and PLGA, and the absence of juglone’s specific peak in 
the JNPs spectrum indicates that juglone was successfully 
coated with the PLGA nanoparticles.
Juglone cumulative release from the nanoparticles in 
phosphate buffer saline at pH 7.4 shows a triphasic pattern 
of up to 30 days (Figure 2D). It starts with 28.62±2.3 % at 
the end of the first hour, then soars to 56.53±2.5 % at the 
end of hour 24, and peaks to 88.86±2.8 % at the end of day 
9. After that, it slows down to finally reach 92.72±4.1 % at 
the end of day 30.
Juglone/JNP effect on fibroblast cell viability
Figure 3 shows the inhibitory effects of juglone and 
JNPs on L929 fibroblast cell viability (measured with the 
MTT assay). In the first 24 h, juglone and JNP had a similar 
cytotoxic effect, with half-maximal inhibitory concentrations 
(IC50) of 290 and 330 µmol/L, respectively (Figure 3A). 
After 48 h, free juglone toxicity became far more prominent, 
with IC50 of 60 µmol/L, as opposed to 270 µmol/L for JNPs 
(Figure 3B). Cell viability drastically dropped at juglone 
concentrations of 83 μmol/L (p=0.038), 160 μmol/L 
(p=0.013), and 250 μmol/L (p=0.034) compared to JNPs. 
In a study by Ramirez et al. (40), high cytotoxic activity of 
synthetic juglone and its derivatives on L929 fibroblast cells 
began at the lowest concentration (5.3 µmol/L) applied. 
Cytotoxic activity this high might be advantageous for 
cancer cell lines, but is unwelcome in other therapeutic 
applications. Significantly lower cytotoxic effect of JNPs 
is therefore an advantage here, most likely thanks to low 
and sustained release from the nanosystem. This is in line 
with reports that biodegradable nanoparticles used as drug 
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carriers protect substances from degradation and reduce 
their toxicity or side effects (41).
Juglone/JNP effect on alfalfa cell viability
Similar to the fibroblast cells, the cytotoxicity of either 
free or nano-encapsulated juglone in alfalfa cells was dose-
dependent and was not significant at doses lower than 27 
and 83 µmol/L, respectively. Similar was reported by other 
studies for alfalfa and other plants (42–47).
Free and nano-encapsulated juglone did not significantly 
differ in their effect on cell viability in the first 24 h either 
(Figure 4A), with respective IC50 of 316 and 382 µmol/L. 
After 48 h, however, free juglone doses of 5 and 27 µmol/L 
had a significantly higher cytotoxic effect (Figure 4B). The 
respective IC50 dropped to 2 µmol/L for juglone and 
70 µmol/L for JNPs.
Ames test findings
According to the spectrophotometric measurements and 
turbidimetric observation (OD600), the juglone dose of 10 
µmol/L was selected as the highest non-cytotoxic 
concentration applied in the Ames test. Figures 5 and 6 
show the results for S. typhimurium TA98 and 100 strains 
in the absence (-S9) and presence (+S9) of metabolic 
activation. Juglone showed mutagenic activity at 2.5 and 
1.25 µmol/L on TA98 strain with S9 metabolic activation 
system but not on TA100 with or without S9. Juglone also 
significantly increased the number of revertant wells at the 
concentration of 0.62 µmol/L in the TA98 strain without 
the S9 medium (B value ≥0.99), but this increase was not 
considered mutagenic, because it still was not twice the 
baseline.
Our results indicate that juglone causes frameshift 
mutations which may be related to hydroxyl substitution. 
In the mutagenicity study carried out on natural quinones 
by Tikkaen et al. (48) hydrocarbons with simple hydroxyl 
and/or methyl substituents were extremely important for 
the mutagenic effect, and while juglone showed a mutagenic 
effect on the TA2637 strain with S9 metabolic activation, 
the effect was extremely weak in the TA98 strain. These 
results are consistent with our study. In another study (49), 
the mutagenic effect of juglone on S. typhimurium TA98 in 
the presence of the S9 metabolic activation system was 
dose-independent, and, according to the authors, related to 
the hydroxyl group at position 5. Besides, juglone is 
biotransformed by liver metabolism and may affect several 
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Figure 2 Particle size distribution (A), scanning electron microscopy image (B), FT-IR spectra (C), and release pattern (D) of nanoparticles
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Figure 3 Viability of L929 fibroblasts treated with free and PLGA nanoparticle-coated juglone (JNP) after 24 h (A) and 48 h (B); Cell 
viability was measured with the MTT assay. Values are expressed as means of quadruple samples with standard error. *statistically 
significant differences between juglone and JNP (p<0.05)
Figure 4 Viability of alfalfa cells treated with free and PLGA nanoparticle-coated juglone (JNP) after 24 h (A) and 48 h (B); Cell 
viability was measured with the MTT assay. Values are expressed as means of triple samples with standard error. *statistically significant 
differences between juglone and JNP (p<0.05)
Figure 5 Potential mutagenicity in S. typhimurium TA98 treated with 0.31−10 μmol/L juglone: (A) TA98-S9 treated with JNPs; (B) 
TA98+S9 treated with JNPs; (C) TA98-S9 treated with free juglone; (D) TA98+S9 treated with free juglone; PC – positive control: 
2-NF (2 µg/mL) and 4-NQO (0.1 µg/mL) without S9 and 2-AA (1 µg/mL) with S9; NC – negative control: water; *B value ≥0.99
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metabolic pathways that are somehow linked to energy 
metabolism. Saling et al. (17) observed that at low 
concentrations juglone stimulated oxygen consumption, 
lowered ATP content, increased the NADH/NAD+ ratio, 
and inhibited gluconeogenesis, whereas at high 
concentrations it triggered ATP production, hyperthermia, 
and even death. In the light of these findings, when S9 is 
added to a juglone-containing environment, products 
resulting from biotransformation by liver enzymes cause 
frameshift mutations in the TA98 strain. S9 is a liver extract 
containing active liver enzymes (P450 activity) which 
simulate hepatic metabolism in in vitro experiments (e.g., 
rat, hamster, or human) (17). In contrast, JNPs did not show 
mutagenic activity (Figure 5 and 6), probably because of 
the sustained and lower release of juglone as PLGA 
nanoparticles degrade. This elimination of mutagenic 
activity is important in terms of genotoxicity, as there is 
little information about the mutagenicity of pharmaceutical 
products using PLGA as carrier. Kruci et al. (50), for 
instance, found no mutagenic activity of PLGA/PHB fibrous 
nanocomposite implants. Similarly, anticancer drugs 
encapsulated in PLGA had toxicity compared to their free-
form counterparts (51). This suggests that JNPs reduce 
genotoxicity and cytotoxicity through similar mechanisms.
CONCLUSION
Our findings have confirmed both the mutagenic and 
cytotoxic effects of free juglone, reported in literature. 
Compared to free juglone, the toxicity of PLGA nanoparticle-
coated juglone was reduced at low doses due to controlled 
release properties. Furthermore, the nanoparticle system 
showed no mutagenicity and improved the biocompatibility 
of juglone, retaining at the same time the beneficial action 
of natural juglone.
Our findings provide important information about 
possible applications of the investigated JNPs. Their IC50 
values were significantly higher than the toxic dose for the 
mutant Salmonella bacteria, which suggests that 
nanoparticle-coated juglone can kill prokaryotic cells 
without damaging eukaryotic cells. In other words, this 
system can be used in pharmaceutical fungicidal and 
bactericidal applications, which remains to be verified by 
future in vitro human cell line studies and in vivo animal 
experiments. Our findings also suggest that nanoparticle-
coated juglone could be used in food safety applications 
and agriculture.
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Citotoksični i mutageni potencijal juglona u slobodnom i nanoinkapsuliranom obliku
Usprkos dokazanim herbicidnim, protubakterijskim, protuvirusnim, protugljivičnim i antioksidacijskim učincima, primjena 
juglona (5-hidroksi-1,4-naftokinon) ograničena je zbog njegove slabe topljivosti u vodi te alelopatskoga i toksičnoga djelovanja. 
Cilj je novijih istraživanja bio ukloniti te prepreke povećanjem njegove topljivosti i boljom regulacijom njegova otpuštanja s 
pomoću sustava nanočestica. Ovo je, međutim, prvo istraživanje u kojem je sintetiziran i karakteriziran juglon u omotaču 
polimernih nanočestica te uspoređen sa slobodnim juglonom u smislu citotoksičnosti u mišjih fibroblasta (L929) i biljnih alfalfa 
stanica te mutagenosti u bakterije Salmonella typhimurium TA98 i TA100. Mišje i biljne stanice izložene slobodno u 
nanoinkapsuliranome juglonu iskazale su smanjenu vijabilnost, koja je ovisila o dozi i vremenu izloženosti, ali je to 
djelovanje bilo značajno slabije s juglonom u nanočesticama pri nižim dozama. Za razliku od slobodnoga juglona, 
nanočestice s juglonom nisu djelovale mutageno na S. typhimurium soj TA98 s metaboličkim aktivacijskim enzimom S9. 
Budući da svi rezultati pokazuju kako je inkapsuliranje juglona u polimerne nanočestice smanjilo njegov toksični i 
mutageni učinak, ovaj oblik ima obećavajući potencijal za primjenu u medicini, poljoprivredi i u području sigurnosti 
hrane.
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